Recognizing and Managing Anaphylaxis in Emergency Practice

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Anaphylaxis is a life-threatening systemic hypersensitivity reaction requiring immediate intervention; classic cutaneous signs like urticaria and angioedema are not universally present, necessitating pattern recognition and response to therapy over definitive diagnostic confirmation.
• Canine presentations commonly include acute gastrointestinal signs (vomiting, diarrhea) followed by collapse, while felines more frequently exhibit respiratory distress, bronchoconstriction, and collapse, sometimes without overt cutaneous changes; cats may also present with bradycardia.
• Epinephrine is the first-line pharmacologic intervention, administered intramuscularly (0.01 mg/kg for dogs and cats) for rapid absorption to reverse vasodilation and hypotension, with intravenous administration reserved for cardiovascular collapse.
• Aggressive isotonic crystalloid fluid resuscitation (15-20 mL/kg for dogs, 10-15 mL/kg for cats, repeated based on perfusion parameters) is crucial to address hypovolemia secondary to vasodilation and increased vascular permeability.
• Early airway management, including intubation for suspected laryngeal edema, and continuous monitoring of pulse quality, heart rate, respiratory effort, SpO₂, blood pressure, and mentation are critical for at least 12-24 hours post-stabilization due to the risk of biphasic reactions.
• Differential diagnoses for acute collapse include severe sepsis, cardiogenic shock, and toxin exposure; response to epinephrine and fluid therapy serves as a diagnostic test, with rapid improvement indicative of anaphylaxis.

Anaphylaxis is an acute, life-threatening systemic hypersensitivity reaction that demands immediate recognition and intervention. This article provides a diagnostic and therapeutic framework for the practicing veterinarian managing suspected anaphylaxis in dogs and cats, with emphasis on atypical presentations, species-specific differences, and the first hour of emergency care. The content addresses the clinical reasoning pathway from triage through stabilization, including epinephrine dosing principles, fluid resuscitation strategy, and monitoring parameters. Vaccine reactions and chronic allergy management are outside the scope of this reference.

The clinical challenge in veterinary emergency practice is that anaphylaxis presents along a spectrum, and classic descriptions of urticaria and facial angioedema do not apply uniformly across species. Dogs frequently show gastrointestinal signs first, while cats may present with respiratory distress or collapse without obvious cutaneous changes. The emergency clinician must therefore maintain a low threshold for initiating anaphylaxis treatment based on pattern recognition and response to therapy, instead of waiting for diagnostic confirmation.

At a Glance

Pathophysiology of Anaphylaxis

Anaphylaxis results from massive release of preformed and newly synthesized mediators from mast cells and basophils. The classic mechanism involves cross-linking of allergen-specific immunoglobulin E on sensitized cells, triggering degranulation. In veterinary patients, the inciting allergen is often identified only retrospectively, and in many cases no trigger is ever confirmed. The same clinical syndrome can occur through immunoglobulin G-mediated pathways, direct mast cell activation by drugs or physical factors, and complement-mediated mechanisms. These non-IgE pathways help explain why anaphylaxis can occur on first known exposure to a drug or venom.

The released mediators, principally histamine, tryptase, platelet-activating factor, and leukotrienes, produce coordinated effects on the vasculature, bronchial smooth muscle, and myocardium. Peripheral vasodilation and increased vascular permeability cause distributive shock, while bronchoconstriction and laryngeal edema compromise ventilation. Myocardial depression and arrhythmias can occur from direct mediator effects and from reduced coronary perfusion. The net result is a state of mixed distributive and hypovolemic shock with a variable respiratory component.

Species-Specific Clinical Patterns

Canine Anaphylaxis

The dog most commonly presents with acute vomiting, diarrhea, or both, often followed by collapse. Cutaneous signs such as urticaria, pruritus, and facial or periocular angioedema are common but not universal. The gastrointestinal signs can mimic acute gastroenteritis, dietary indiscretion, or toxin ingestion, and the clinician must look for concurrent evidence of vasodilation, such as injected mucous membranes, tachycardia, and weak pulses. Hepatic congestion and acute gastrointestinal hemorrhage can occur in severe cases.

Feline Anaphylaxis

Cats more frequently show respiratory signs, including tachypnea, dyspnea, and wheezing, reflecting prominent bronchoconstriction. They may also present with vomiting, diarrhea, or acute collapse. Cutaneous signs in cats are often subtle and may be limited to facial pruritus or erythema. Cats can be profoundly hypotensive with bradycardia instead of tachycardia, a pattern that differs from the typical canine response and can confuse the initial assessment. The MSD Veterinary Manual describes these species differences in clinical presentation and emphasizes that feline anaphylaxis may be mistaken for asthma or heart failure.

Immediate Assessment and Triage

The first step is a rapid primary survey focused on the airway, breathing, and circulation. A patient with stertor, stridor, or increased respiratory effort requires immediate airway assessment, as laryngeal edema can progress to complete obstruction within minutes. Pulse quality and heart rate are assessed simultaneously, and the clinician should note whether the patient is alert, obtunded, or comatose. Capillary refill time and mucous membrane color provide additional perfusion information, though they are less reliable in cats.

A focused history is obtained concurrently with the examination. The owner is asked about recent vaccination, drug administration, insect stings, dietary changes, or exposure to new household products. The timing of exposure relative to sign onset is recorded, as anaphylaxis typically develops within minutes to a few hours of exposure. However, the absence of a known trigger does not exclude the diagnosis, and treatment decisions should not be delayed while pursuing historical details.

Differential Diagnosis

The differential diagnosis for acute collapse with gastrointestinal or respiratory signs is broad. Severe sepsis and septic shock can produce indistinguishable clinical findings, particularly in the early phase. Cardiogenic shock from arrhythmias or myocardial failure may present with collapse and poor perfusion. Toxin exposures, including chocolate, xylitol, and organophosphates, can cause vomiting, collapse, and altered mentation. Upper airway obstruction from foreign bodies, laryngeal paralysis, or tracheal collapse must be considered in dyspneic patients. Heat stroke and severe pain can also produce vasodilation and collapse.

The diagnostic approach is pragmatic. Point-of-care lactate, blood glucose, and packed cell volume can help differentiate hypoperfusion from metabolic causes. Thoracic radiographs or point-of-care ultrasound may identify pulmonary edema, pleural effusion, or a foreign body. An electrocardiogram is indicated if arrhythmias are suspected. The response to epinephrine and fluid therapy is itself a diagnostic test, as patients with anaphylaxis typically improve rapidly, while those with sepsis or cardiogenic shock show a more limited or transient response. The RECOVER Initiative guidelines for cardiopulmonary resuscitation provide a structured approach to the patient that deteriorates to cardiac arrest during the initial assessment, and these protocols should be reviewed in advance by emergency teams.

Initial Stabilization: Airway, Breathing, Circulation

Airway management takes priority. Patients with evidence of upper airway obstruction are intubated early, before edema progresses. If intubation is not immediately possible, the clinician should prepare for an emergency tracheostomy. Oxygen is administered by mask, flow-by, or nasal cannula to all dyspneic patients, and pulse oximetry is used to guide supplementation. Cats with bronchoconstriction may benefit from bronchodilator therapy, though this does not replace epinephrine as the primary treatment.

Vascular access is obtained immediately. Two peripheral catheters are ideal in the unstable patient, but one large-bore catheter is acceptable if access is difficult. Intraosseous access is a viable alternative in small patients or those with severe hypotension. Blood samples are collected at the time of catheter placement for baseline hematology, biochemistry, lactate, and blood gas analysis, but treatment is not delayed for these results.

Epinephrine Administration

Epinephrine remains the primary pharmacologic intervention for anaphylaxis in dogs and cats. Its alpha-adrenergic effects reverse vasodilation and hypotension, while beta-adrenergic effects bronchodilate, increase cardiac contractility, and reduce mediator release from mast cells and basophils. The drug must be given early, delayed administration is associated with poorer outcomes.

The intramuscular route is preferred for initial therapy in most patients because it provides rapid absorption and a more predictable plasma concentration profile than subcutaneous administration. The vastus lateralis or epaxial musculature is appropriate. Intravenous administration is reserved for patients in cardiovascular collapse with absent perfusion, and it carries a higher risk of arrhythmias and severe hypertension. When IV access is already established and the patient is moribund, a dilute bolus given slowly with continuous electrocardiographic monitoring is acceptable. Intraosseous administration is an alternative when vascular access cannot be obtained.

Current formulary references should be consulted for species-specific dosing, but the following framework reflects consensus emergency practice. For dogs, the IM dose is 0.01 mg/kg of 1 mg/mL epinephrine. For cats, the same IM dose is used, though some references recommend a slightly lower range. The IV dose, when required, is 0.005 to 0.01 mg/kg given slowly. Repeat IM dosing can be given every 5 to 15 minutes based on clinical response. A constant rate infusion of epinephrine at 0.05 to 0.2 mcg/kg/min may be used for refractory hypotension, titrated to effect.

Verify all doses against a current veterinary formulary before administration. Patient size, comorbidities, and concurrent medications alter the risk of adverse effects. Cats are particularly sensitive to the arrhythmogenic effects of epinephrine, so dose reduction and slower administration are prudent.

Fluid Resuscitation and Cardiovascular Support

Hypovolemia in anaphylaxis results from massive venodilation, increased capillary permeability, and third-space fluid loss. Aggressive crystalloid resuscitation is the second pillar of initial therapy. One or two large-bore intravenous catheters should be placed immediately. If peripheral access fails, consider intraosseous catheterization, particularly in cats and small dogs.

The 2024 AAHA and AAFP fluid therapy guidelines emphasize individualized resuscitation based on perfusion parameters instead of fixed volumes. A common starting point is a 15 to 20 mL/kg bolus of isotonic crystalloid given over 10 to 20 minutes in dogs, and 10 to 15 mL/kg in cats. Repeat boluses are guided by heart rate, pulse quality, mucous membrane color, capillary refill time, blood pressure, and lactate. Cats tolerate volume overload poorly, so smaller, more frequent boluses with frequent reassessment are safer.

Synthetic colloids such as hydroxyethyl starch are no longer recommended as first-line resuscitation fluids in small animals due to evidence of renal injury and coagulopathy. If crystalloid resuscitation alone fails to restore perfusion, consider a vasopressor infusion instead of additional large-volume crystalloid. Norepinephrine or vasopressin constant rate infusions may be used in patients with persistent hypotension despite adequate volume replacement. These drugs require central venous access when possible and continuous blood pressure monitoring.

Blood pressure targets should be a mean arterial pressure of 60 to 70 mm Hg or a systolic pressure of 90 to 100 mm Hg. Doppler ultrasound or oscillometric devices are acceptable when invasive monitoring is unavailable, but invasive arterial pressure is preferred in unstable patients. Serial lactate measurement helps assess the adequacy of resuscitation, with normalization indicating improved tissue perfusion.

Adjunctive Pharmacotherapy

Antihistamines do not reverse established anaphylaxis and should never replace epinephrine. They may reduce cutaneous signs and pruritus but have no role in treating hypotension or bronchoconstriction. H1 antagonists such as diphenhydramine can be given IM or slow IV at formulary doses. H2 antagonists such as famotidine are sometimes added for gastrointestinal signs, though evidence for benefit is limited.

Glucocorticoids are commonly administered to treat or prevent biphasic reactions, but the evidence base for this practice is weak. No prospective veterinary studies demonstrate improved outcomes with corticosteroid use in anaphylaxis. If used, a short-acting agent such as dexamethasone sodium phosphate at a single anti-inflammatory dose is reasonable. The drug should not be given before epinephrine and should not delay fluid resuscitation.

Bronchodilators are indicated for patients with persistent bronchoconstriction after epinephrine. Inhaled albuterol can be administered via a spacer device adapted for veterinary use. Aminophylline is a second-line option for cats with severe bronchospasm, but it should be used cautiously due to a narrow therapeutic index and the risk of tachyarrhythmias.

Atropine is reserved for patients with bradycardia that persists after epinephrine and fluid resuscitation. It is not a routine component of anaphylaxis treatment. Glucagon may be considered in patients taking beta-blockers, since these drugs blunt the response to epinephrine. Glucagon bypasses beta-receptors and increases intracellular cyclic AMP. Its use is uncommon in veterinary practice but should be remembered when a patient on beta-blocker therapy fails to respond to standard treatment.

Monitoring and Documentation

Continuous monitoring is required for at least 12 to 24 hours after initial stabilization. The RECOVER initiative guidelines emphasize serial assessment of perfusion parameters and early recognition of deterioration. Heart rate and rhythm, respiratory rate and effort, pulse quality, mucous membrane color, capillary refill time, and blood pressure should be recorded at least every 15 minutes during the acute phase, then at decreasing frequency as the patient stabilizes.

Pulse oximetry provides a continuous estimate of hemoglobin saturation and detects early hypoxemia. Capnography, when available, offers a more immediate indicator of ventilation and perfusion. End-tidal carbon dioxide falls with decreased cardiac output and rises with bronchospasm and air trapping. Serial blood gas analysis quantifies acid-base status and ventilation.

Document the time of onset, suspected trigger, all drugs administered with doses and routes, fluid volumes, and physiologic parameters at each assessment. Record the response to each intervention. This documentation supports clinical decision-making during the observation period and provides a clear record if the patient deteriorates. The AVMA practice resources offer guidance on medical record standards that apply to emergency presentations.

Biphasic reactions occur in a subset of patients, with recurrence of signs hours after apparent resolution. The reported incidence varies widely, and the evidence base in veterinary medicine is limited. Observe all patients for a minimum of 8 to 12 hours after resolution of clinical signs. Patients with severe initial presentations, those requiring repeated epinephrine doses, and those with cardiovascular collapse warrant longer observation, up to 24 hours. Discharge instructions should include specific criteria for immediate re-presentation.

When to Escalate Care

Escalation is required when a patient fails to respond to initial epinephrine and fluid resuscitation. Persistent hypotension, worsening mentation, progressive respiratory distress, or cardiac arrhythmias mandate a higher level of intervention. Reassess the diagnosis at this point. Conditions that mimic anaphylaxis, including severe sepsis, acute heart failure, pulmonary thromboembolism, and airway obstruction, may require different therapy.

Consider transfer to a referral facility when the patient requires mechanical ventilation, continuous vasopressor infusion, or advanced hemodynamic monitoring that the current practice cannot provide. Stabilize the patient to the extent possible before transport, maintain IV access, and communicate the treatment history to the receiving clinician. The RECOVER initiative guidelines provide a framework for managing cardiopulmonary arrest, which remains the most extreme escalation scenario in anaphylaxis.

Recognized Complications and Failure Modes

Anaphylaxis can evolve through several distinct failure modes even when initial treatment appears appropriate. The most consequential is refractory hypotension despite epinephrine and fluid resuscitation. This pattern suggests either ongoing mediator release from a persistent antigen depot, inadequate epinephrine dosing, or unrecognized concurrent disease such as cardiac compromise. Serial blood pressure measurement, ideally with a Doppler or oscillometric device, every five minutes during the first hour distinguishes transient responsiveness from true refractoriness.

Pulmonary complications differ by species. Dogs may develop severe bronchoconstriction and pulmonary hypertension, while cats more often show bronchospasm with wheezing and expiratory effort. Both species can progress to noncardiogenic pulmonary edema. Early detection relies on serial respiratory rate, effort scoring, and pulse oximetry. A declining SpO2 despite improved perfusion should prompt thoracic imaging instead of assumption of simple sedation.

Coagulopathy represents a less common but potentially fatal complication. Dogs with severe anaphylaxis can develop disseminated intravascular coagulation with petechiae, prolonged clotting times, or unexplained bleeding from catheter sites. Cats appear less susceptible, but any patient with persistent tachycardia or poor perfusion after apparent stabilization warrants a platelet estimate and clotting profile.

Gastrointestinal injury follows splanchnic ischemia in dogs. Hematemesis, melena, or abdominal pain appearing hours after the initial event indicates mucosal damage. Serial abdominal palpation and monitoring of vomitus and feces for blood detect this complication before overt shock recurs.

Common Errors and Corrective Actions

Less experienced clinicians commonly mistake the initial excitement phase in dogs, with vomiting, urination, and defecation, for a gastrointestinal emergency or toxin exposure. The presence of facial angioedema or urticaria should redirect the differential toward anaphylaxis even when gastrointestinal signs dominate. Another frequent error is delaying epinephrine while placing intravenous catheters or calculating doses. Intramuscular epinephrine can be given immediately, and the RECOVER veterinary CPR guidelines emphasize time-critical intervention in cardiovascular collapse.

A third error involves fluid selection and rate. Crystalloids remain the first-line choice, but the AAHA and AAFP fluid therapy guidelines stress that rate must be titrated to perfusion parameters instead of administered as a fixed volume. Overzealous bolusing in a patient with myocardial dysfunction can precipitate pulmonary edema.

Evidence Limitations and Areas of Expert Disagreement

The evidence base for anaphylaxis management in dogs and cats is largely extrapolated from human medicine and experimental models. Prospective randomized trials comparing epinephrine routes, fluid strategies, or adjunctive therapies in clinical veterinary patients are scarce. The MSD Veterinary Manual presents current clinical guidance, but much of it rests on expert opinion and physiologic reasoning instead of controlled data.

Expert opinion diverges on several points. The optimal epinephrine route for the unstable patient remains contested, with some authorities favoring intravenous administration despite arrhythmia risk and others preferring intramuscular delivery. The role of glucocorticoids in preventing biphasic reactions is similarly debated. Some clinicians administer them routinely, while others reserve them for refractory cases, citing weak evidence of benefit. Antihistamine use, particularly H1 blockade, is widely accepted, but whether H2 antagonism adds meaningful benefit is unclear.

Monitoring duration after apparent recovery is another area without consensus. Recommendations range from 8 to 24 hours, and the risk of biphasic reactions in veterinary patients is not well characterized. The International Consensus Statement on Allergy and Rhinology addresses human allergic disease and highlights the general difficulty of standardizing definitions and outcomes across allergic conditions, a limitation that applies equally to veterinary anaphylaxis research.

Escalation, Referral, and Reporting

Patients with refractory hypotension, persistent arrhythmias, severe respiratory compromise, or suspected coagulopathy warrant transfer to a facility with continuous monitoring and 24-hour critical care capability. Early telephone consultation with a specialist or emergency center is appropriate when local resources are limited. Laboratory support should include serial blood gas analysis, lactate measurement, coagulation panels, and thoracic imaging when pulmonary complications are suspected.

Regulatory reporting is rarely required for anaphylaxis itself, but suspected adverse drug reactions, including reactions to vaccines, antimicrobials, or other pharmaceuticals, should be reported through the appropriate pharmacovigilance system. The AVMA practice resources provide guidance on adverse event reporting obligations. Where anaphylaxis follows a venomous bite or sting, regional poison control or public health authorities may require notification, and the WOAH terrestrial animal health standards may apply when the event involves reportable diseases or regulated products. Clinicians should document the suspected trigger, timing, treatment, and outcome in the medical record to support both clinical follow-up and any required reporting.

Frequently Asked Questions

How do I manage anaphylaxis when intravenous access cannot be obtained quickly?

Intraosseous catheterization is the preferred alternative when peripheral venous access fails, particularly in hypotensive or collapsed patients. The proximal humerus or femur provides rapid access to the central circulation with flow rates comparable to peripheral venous catheters. If intraosseous placement is not feasible, the intranasal route can deliver epinephrine and atropine through mucosal absorption, though onset is slower and less predictable. Intramuscular epinephrine into the epaxial or quadriceps musculature remains a viable option when no vascular access exists. Administer fluids through any available route while working to establish definitive access. The RECOVER veterinary CPR guidelines address vascular access strategies during resuscitation and should inform your approach when standard routes fail.

What monitoring parameters matter most during the first hour after epinephrine administration?

Serial blood pressure, heart rate, respiratory rate, and mentation form the core monitoring set. Hypotension that persists beyond 10 to 15 minutes after epinephrine suggests either inadequate dosing, ongoing vasodilation, or unrecognized blood loss. Pulse quality and mucous membrane color should improve within 5 minutes of effective treatment. Lactate trends, measured at presentation and again at 60 to 90 minutes, provide objective evidence of perfusion recovery. Continuous electrocardiography is warranted because epinephrine can provoke tachyarrhythmias, particularly in patients with preexisting cardiac disease. Urine output, when measurable, confirms renal perfusion. The AAHA/AAFP fluid therapy guidelines describe monitoring parameters that distinguish adequate resuscitation from over-resuscitation.

How does anaphylaxis management differ in brachycephalic breeds?

Brachycephalic patients present with a narrower margin for airway compromise. Their elongated soft palates, stenotic nares, and everted laryngeal saccules reduce baseline airway diameter, so mucosal edema that would be manageable in a normocephalic dog can cause rapid obstruction. Secure the airway earlier in these patients. Place an endotracheal tube at the first sign of laryngeal edema instead of waiting for audible stridor or cyanosis. Sedation requirements differ as well, since drugs that reduce upper airway tone, such as acepromazine or high-dose opioids, can precipitate collapse of pharyngeal soft tissues. Maintain the patient in sternal recumbency with the head elevated until extubation is certain. The MSD Veterinary Manual provides breed-specific considerations for airway management that apply directly to this scenario.

What should I document in the medical record after an anaphylactic event?

Record the suspected trigger, time of exposure, and time of first clinical signs. Document each drug administered with the exact dose, route, and time, including epinephrine, fluids, and adjunctive agents. Note the patient's response to each intervention, including blood pressure, heart rate, and respiratory parameters at defined time points. Describe the progression of clinical signs, particularly any that were atypical for the species. Include photographs of skin lesions or angioedema when present. Document client communication, including the suspected trigger, expected course, and signs that should prompt recheck. The AVMA practice resources offer guidance on medical record standards that support both continuity of care and medicolegal defense.

How do I counsel an owner about the risk of recurrence after the patient is discharged?

Explain that recurrence is possible with re-exposure to the same trigger, and that the severity of the second reaction cannot be predicted from the first. Advise owners to identify and avoid the suspected trigger when possible, and to seek immediate veterinary care if clinical signs recur. For patients with venom or vaccine reactions, discuss the option of premedication protocols with the primary care veterinarian. Clarify that antihistamines alone are not adequate treatment for a severe reaction and should never replace epinephrine. Provide written instructions describing the signs that warrant emergency evaluation. The International Consensus Statement on Allergy and Rhinology discusses allergen avoidance strategies that translate to veterinary patient counseling.

What do I do when a patient deteriorates despite apparently adequate initial treatment?

Reassess the three pillars of resuscitation in sequence. Confirm the airway is patent and the endotracheal tube, if present, has not migrated. Verify that intravenous or intraosseous access is truly intravascular, since a displaced catheter will produce apparent treatment failure. Recalculate the epinephrine dose against the patient's current weight, because dosing errors are a recognized cause of inadequate response. Consider whether the diagnosis is correct, since conditions such as severe sepsis, cardiogenic shock, or anaphylaxis with concurrent hemorrhage require different therapy. Repeat the focused physical examination, including abdominal palpation and thoracic auscultation, to identify new findings. The RECOVER guidelines provide a structured approach to reassessment during resuscitation that applies when the initial response is insufficient.

Related Clinical & Scientific Guides

• Toxicology in Emergency Practice: Common Poisons and Diagnostic Approach
• Veterinary Cardiopulmonary Resuscitation: Post-Cardiac Arrest Care
• Fluid Therapy Guidelines for Dogs and Cats: A Practical Update

References and Further Reading

• International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.. 2018.
• RECOVER Initiative Veterinary CPR Guidelines. Veterinary Emergency and Critical Care Society.
• AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats. AAHA.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Toxicology in Emergency Practice: Common Poisons and Diagnostic Approach
• Capnography in Veterinary Emergency and Critical Care
• Veterinary Electrocardiography in Emergency and Critical Care
• Veterinary Plasma Transfusion: Indications and Administration
• Veterinary Shock: Compensatory Mechanisms and Progression

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.